• AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

    1 month ago - By Xconomy

    After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and cardiovascular diseases. Under the collaboration, expected to last multiple years, Gatehouse will use its sRNAlytics platform to identify small RNA signatures, which the company says help in diagnosing and subtyping diseases from human samples. Financial terms were not disclosed. “The small RNA signatures point to disrupted biological pathways that can be backfit into the known mechanism of action for a drug or...
    Read more ...